Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Italfarmaco S.p.A
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, ITF will use NMS’s proprietary linker-payload technology to develop a novel peptide-drug conjugate (PDC) to bring first- and best-in-class personalized medicines to cancer patients.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
December 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Italfarmaco S.p.A
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Solve Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, SolveTx will use NMS's proprietary linker-payload technology to develop and commercialize novel antibody-drug conjugates (ADCs) for up to four cancer targets selected by SolveTx.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 05, 2023
Lead Product(s) : Antibody-drug Conjugate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Solve Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : NMS-293
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or with DNA damage response inhibitors, in numerous tumor types.
Brand Name : NMS-03305293
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 21, 2022
Lead Product(s) : NMS-293
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?